Changes in the purinergic tumor environment can promote or inhibit tumor growth, depending on tumor type, extracellular nucleotide and nucleoside concentrations, and the expression levels and distribution patterns of purinergic receptor subtypes in tumor and immune cells [8,17]. The gene discussed is P2RX4; the disease is neoplasm.